Management of Hypertension in Dialysis Patients

Primary Recommendations

• The National Kidney Foundation's K/DOQI guidelines recommend carvedilol as the first-choice beta-blocker for dialysis patients with cardiovascular disease or heart failure, based on a "Moderately Strong" recommendation supported by randomized trial evidence, providing a comparable degree of improvement to that seen in the general population 1
• The American College of Cardiology recommends starting with 3.125 mg of carvedilol twice daily and titrating upward based on tolerance and blood pressure response in dialysis patients with uncontrolled hypertension 1
• The K/DOQI guidelines suggest that beta-blockers should be prioritized as first-line therapy in dialysis patients with previous myocardial infarction, well-established coronary artery disease, systolic heart failure, or dilated cardiomyopathy, as they are associated with decreased mortality in these populations 1, 3, 4

Alternative Therapies

• The National Kidney Foundation's K/DOQI guidelines recommend atenolol as an alternative beta-blocker for noncompliant patients, which can be administered three times weekly under direct supervision, providing a unique advantage in this population 1
• Atenolol lacks the mortality benefit demonstrated for carvedilol in dialysis patients with heart failure, and does not provide the vasodilatory effects of carvedilol 1

Target Blood Pressure

• The K/DOQI guidelines recommend aiming for a predialysis blood pressure of <140/90 mmHg without substantial orthostatic hypotension or symptomatic intradialytic hypotension, to minimize left ventricular hypertrophy and mortality risk in dialysis patients 3, 5

Critical Pitfalls to Avoid

• The American College of Cardiology recommends avoiding the use of sotalol in dialysis patients due to the increased risk of torsade de pointes, and avoiding abrupt discontinuation of beta-blockers to prevent rebound hypertension and potential cardiovascular events 4, 6
• The American Journal of Kidney Diseases recommends monitoring for intradialytic hypotension and avoiding beta-blockers with intrinsic sympathomimetic activity in patients with ischemic heart disease or heart failure 2, 6